We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Chronic Hepatitis B Virus Draft Guidance
FDA Issues Chronic Hepatitis B Virus Draft Guidance
Clinical trials of drugs for treatment of chronic hepatitis B viral infections may use multiple efficacy endpoints, the FDA said in new draft guidance released Thursday.